(Q34674780)

3 August 2017

1 reference

title

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications (English)

1 reference

3 August 2017

Yu-Sen Wang

1

1 reference

3 August 2017

Stephen Youngster

2

1 reference

3 August 2017

Michael Grace

3

1 reference

3 August 2017

James Bausch

4

1 reference

3 August 2017

Ronald Bordens

5

1 reference

3 August 2017

Daniel F Wyss

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Advanced Drug Delivery Reviews

3 August 2017

1 reference

3 August 2017

54

1 reference

3 August 2017

4

1 reference

3 August 2017

547-570

1 reference

Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Pegylated liposomal adriamycin: a review of current and future applications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Colloidal systems for tumor targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

The scientific challenge of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Humans as the world's greatest evolutionary force

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Biomedical and biotechnological applications of PEG- and PM-modified proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Objective antiviral assay of the interferons by computer assisted data collection and analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Lymphokine-activated killer cells, natural killer cells and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Immunoregulatory properties of ISG15, an interferon-induced cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Alpha and beta interferons and their receptor and their friends and relations.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Functionally important conserved amino-acids in interferon-alpha 2 identified with analogues produced from synthetic genes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Initial and innate responses to viral infections--pattern setting in immunity or disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900027-3

7 January 2021

10.1016/S0169-409X(02)00027-3

Identifiers

DOI

1 reference

3 August 2017

1 reference